Foreign institutional investors (FIIs) have hiked their shareholding in pharma major, Lupin, to historic highs of 28.8% in March 2013 quarter from 27.76% at the end of December 2012 quarter. FIIs bought 4.66 million shares worth of Rs 279 crore in January-March quarter.
Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).
